NHS-Industry Partnerships that deliver for patients
At CHASE, we specialise in designing, deploying and managing partnerships that connect the life sciences industry with the NHS.
We help pharmaceutical, biotech and medtech organisations create programmes that deliver measurable results for patients, alleviate NHS capacity challenges and ensure medicines and technologies reach the people who need them most.
-7.avif)
“I would highly recommend CHASE as a go-to organisation to deliver service improvement initiatives that could benefit both pharma and the wider NHS.”
Director of Medicine Engagement
Why NHS-Industry Partnerships matter
The NHS cannot solve its capacity challenges alone. Nor should it have to. The case for industry partnership has never been stronger and the frameworks to create partnerships and collaborative working projects that work within the NHS are clearly defined.
With guidance from the ABPI and NHS Confederation, well-designed partnerships deliver: improved patient outcomes, more efficient NHS operations and better alignment with industry goals. Life sciences companies are expanding their market access and healthcare partnership teams, while NHS systems are actively seeking collaborative projects that drive patient care innovation.
CHASE has been designing and delivering these partnerships for a number of years. We know what works and what the NHS needs to say yes.
Key benefits of working with CHASE
Partnering with CHASE delivers tangible outcomes that stand the test of time.
Here’s how we create value for all stakeholders:
For patients
Improved access to innovative medicines and technologies, optimised care pathways and reduced health inequalities.
For the NHS
Alleviated capacity challenges, improved clinical workflows and enhanced patient experiences, with programmes designed for long-term sustainability, not short-term impact.
For industry
Assurance that medicines and technology are effectively deployed and reaching the patients who need them most, with independent evidence to prove it.
ABPI-aligned by design
Every programme we design is built in accordance with ABPI collaborative working guidelines, NHS Confederation frameworks and The King’s Fund guidance, protecting all parties and maximising programme credibility.
Clinician-led from the outset
Our team includes NHS clinicians with first-hand experience of the systems your programme will operate within. Every project is designed with NHS clinician input, guaranteeing lasting impact and real-world scalability.
What we deliver
Tailored programmes for better patient pathways
From patient recall systems to seamless integration between primary and secondary care, our programmes are strategically designed with NHS clinician input. Whether it is optimising referral processes, reducing unnecessary hospital admissions or improving medicine adherence, every solution is built around real clinical need.
Real-time insights through Medacy
Through Medacy, our sister company, we deliver pharmacist-led clinical programmes directly into NHS settings, enabling 5 million+ patient interactions annually. This hands-on delivery ensures our programmes are backed by actionable real-world insights, not just theory.
Examples of solutions we offer:
Patient recall systems: Enhancing follow-up care and improving adherence to treatment plans
Care pathway innovation: Streamlining operations to reduce hospital admissions and improve patient satisfaction
Clinical data and audit outcomes: demonstrating the value of industry contributions with robust, independent reporting
-6.avif)
Roles we deploy
As well as redesigning patient pathways, we deploy a diverse range of clinical and operational roles to deliver NHS-industry programmes.
Strategic NHS integration: from data to delivery
CHASE has partnered with HSJ Advisory to offer senior pharma and medtech leaders a uniquely integrated service for NHS-industry programme design and delivery. HSJ Advisory brings licensed NHS data intelligence and independent validation; CHASE and Medacy bring the clinical teams and operational expertise to make it happen. Together, we bridge the gap between NHS strategy and operational reality.
The five-step delivery model
1 - Strategic design
HSJ Advisory uses licensed NHS Hospital Episode Statistics (HES) and prescribing data to map patient access and align your commercial or clinical proposition with national and local NHS priorities.
2 - Specialist implementation
CHASE and Medacy deploy the expert clinical and commercial teams required to execute the strategy within NHS settings.
3 - Objective guidance
HSJ Advisory independently validates programme impact by reviewing hospital activity and prescribing data, providing a level of real-world evidence that global consultancies often cannot replicate.
4 - Sustainable legacy
CHASE ensures the value of the programme outlasts our presence, training NHS staff, embedding automated systems and enabling the NHS to maintain the service independently after our active involvement ends.
5 - Market awareness
Successful outcomes are shared via HSJ’s journals, webinars, events and white papers, establishing your leadership in the therapeutic area with a credible, independent platform.
An agile alternative to global consultancies
As independent, UK-based experts, the CHASE and HSJ Advisory partnership combines licensed NHS data, clinical delivery capability and independent real-world evidence — with the agility and accountability that global firms cannot match.
Our network and expertise
Our success is built on trust, expertise and an unparalleled understanding of the NHS landscape.
Trusted Clinical Practitioners
Our team includes NHS clinicians with first-hand experience, ensuring practical and actionable strategies from day one.Extensive NHS Network
Relationships with NHS ICBs, ICSs, Trusts, PCNs, Health Innovation Networks and primary and secondary care providers allow us to fast-track project implementation.Sustainable Results
Every programme is designed with long-term sustainability in mind, ensuring lasting improvements for patients, the NHS and industry partners.
-6.avif)
Transforming specialist care through NHS–Industry Partnership
CHASE partnered with a client and the NHS to launch a local specialist service, improving access to biologics and cutting delays for underserved UK patients.
"Many thanks for all CHASE’s efforts in leading this important work through an extremely challenging time for the NHS.
Your attention to detail, co-ordination of all the moving parts and ability to drive the project forward has been exemplary.
Albeit we have been delayed by the pandemic, I know we would not have delivered the results achieved so far, without your efforts and for this CHASE deserve massive credit.
My experience has been such that I would highly recommend CHASE as a go-to organisation to deliver both R&D projects, or service improvement initiatives that could benefit both pharma and the wider NHS."
Director of Medicine Engagement
"I wanted to recognise what brilliant partners CHASE have been to our team over the last few months, playing a vital role in helping us deliver this critical project at such high pace.
Steve in the early phases, and then Emma, Huw & Danny as regular members of the Project Team. Huw, of note, your early leadership in the Project Team, leaning on past experience of how to run the process alongside our other supplier was particularly helpful in those first weeks.
To the whole team, your responsiveness, pragmatism and positive energy has been first class throughout."
Commercial Business Unit Director
"CHASE have been trusted partners for over a decade and provide us with a high-quality outsourced specialist sales team, plus excellent wrap around service, pastoral care and consultancy.
When we recently launched a new Oncology product, the CHASE sales team was instrumental in this. I am regularly approached by other contract sales providers and have no hesitation in saying “no thank you.”
UK Commercial Director
"The collaboration with CHASE was instrumental in ensuring the study could be delivered on time and on budget.
In addition, CHASE facilitated, through site networks and agile research nurse placements, the delivery of the UK recruitment target 3 months ahead of plan."
Head of Clinical Operations UK & Ireland
NHS-Industry Partnership news
Explore our latest thinking, event updates and industry insights about NHS-industry partnerships.
NHS neighbourhood health: lessons from Kent and Medway
Kent and Medway has signed the first local variation of the PCN DES, worth £10 million a year. CHASE assesses what the framework still leaves unsettled.
NHS Carbon Reduction Plan 2027: a harder test for suppliers
From April 2027, NHS Carbon Reduction Plan rules demand full scope 3 emissions data. CHASE assesses what this means for pharma and medtech suppliers.
Yvette Cooper as health secretary: what the reshuffle means for pharma, medtech and the NHS
Yvette Cooper is the UK's new health secretary after a reshuffle that also reshaped the medtech brief. Here's what it means for pharma, medtech and NHS teams.
Ready to design your NHS-industry partnership?
The future of healthcare requires innovation, collaboration and strategic partnerships. CHASE is here to make it happen — from design to delivery to lasting legacy.
.svg)
